BridgeMD
New treatment option for Advanced Epithelial Ovarian Cancer
Official title Intensification Treatment of Ovarian Cancer by PIPAC
ClinicalTrials.gov ID: NCT07514494
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and visually detectable peritoneal carcinomatosis. The main questions are whether repeated PIPAC increases the rate of complete surgical cytoreduction (CRS R0) and whether it improves disease control, survival outcomes, and safety compared with standard combined treatment including a single PIPAC procedure.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Female, age 18-75 years.
- Histologically verified ovarian cancer with peritoneal carcinomatosis.
- FIGO stage IIIB or IIIC.
- visually detectable peritoneal carcinomatosis.
- Peritoneal metastatic involvement documented preoperatively by ultrasound, CT, MRI, PET-CT, or equivalent imaging.
You likely can't join if
- Age \> 75 years; ECOG 3-4; cachexia with BMI \<= 16.
- Severe concomitant disease in exacerbation or decompensation.
- Extra-abdominal metastases, including metastatic pleuritis.
- Mucinous ovarian carcinoma or another active malignant neoplasm, except malignancies in clinical remission for more than 2 years.
- Pronounced adhesive disease of the abdominal cavity.
- Pregnancy or breastfeeding.
See the full eligibility criteria
- Female, age 18-75 years.
- Histologically verified ovarian cancer with peritoneal carcinomatosis.
- FIGO stage IIIB or IIIC.
- visually detectable peritoneal carcinomatosis.
- Peritoneal metastatic involvement documented preoperatively by ultrasound, CT, MRI, PET-CT, or equivalent imaging.
- Ability to comply with protocol procedures and provide written informed consent.
- Age \> 75 years; ECOG 3-4; cachexia with BMI \<= 16.
- Severe concomitant disease in exacerbation or decompensation.
- Extra-abdominal metastases, including metastatic pleuritis.
- Mucinous ovarian carcinoma or another active malignant neoplasm, except malignancies in clinical remission for more than 2 years.
- Pronounced adhesive disease of the abdominal cavity.
- Pregnancy or breastfeeding.
- Positive BRCA1 or BRCA2 status.
- Any condition precluding safe PIPAC or protocol execution, including hollow-organ perforation, gastrointestinal resection with anastomosis, or repair of a hollow-viscus defect.
- Refusal of treatment at any study stage.
The study team makes the final eligibility decision.
Where it's taking place
- Balashikha, Russia
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Balashikha, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.